Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study.

Autor:	Collea RP; US Oncology Research, McKesson Specialty Health, The Woodlands; New York Oncology Hematology Center, Albany. Electronic address: rufus.collea@usoncology.com., Kruter FW; US Oncology Research, McKesson Specialty Health, The Woodlands; Alliance Hematology-Oncology PA, Westminster., Cantrell JE; US Oncology Research, McKesson Specialty Health, The Woodlands; Birmingham Hematology-Oncology, Birmingham., George TK; US Oncology Research, McKesson Specialty Health, The Woodlands; Texas Oncology, Odessa., Kruger S; US Oncology Research, McKesson Specialty Health, The Woodlands; Virginia Oncology Associates, Hampton., Favret AM; US Oncology Research, McKesson Specialty Health, The Woodlands; Northern Virginia Hematology-Oncology, Fairfax., Lindquist DL; US Oncology Research, McKesson Specialty Health, The Woodlands; Arizona Oncology, Sedona., Melnyk AM; US Oncology Research, McKesson Specialty Health, The Woodlands; Texas Oncology, Abilene., Pluenneke RE; US Oncology Research, McKesson Specialty Health, The Woodlands; Kansas City Cancer Center, Kansas City., Shao SH; US Oncology Research, McKesson Specialty Health, The Woodlands; Northwest Cancer Specialists, Portland., Crockett MW; US Oncology Research, McKesson Specialty Health, The Woodlands., Asmar L; US Oncology Research, McKesson Specialty Health, The Woodlands., O'Shaughnessy J; US Oncology Research, McKesson Specialty Health, The Woodlands; Texas Oncology, PA, Baylor-Charles A. Sammons Cancer Center, Dallas, USA.
Jazyk:	angličtina
Zdroj:	Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2012 Oct; Vol. 23 (10), pp. 2599-2605. Date of Electronic Publication: 2012 Mar 19.
DOI:	10.1093/annonc/mds052
Abstrakt:	Background: We determined the objective response rates produced by pegylated liposomal doxorubicin (PLD) plus carboplatin with/without trastuzumab (Herceptin). Patients and Methods: Patients with measurable disease were stratified by taxane treatment history and human epidermal growth factor receptor-2 status. Treatment: PLD 30 mg/m(2) followed by carboplatin, day 1 of each 28-day cycle; human epidermal growth factor receptor-2 (HER2)-positive patients also received trastuzumab. Results: Arm 1 received PLD plus carboplatin (N = 41 arm 1a, taxane naive; N = 42 arm 1b, taxane pretreated); Arm 2 patients received PLD plus carboplatin + Herceptin (N = 46). Overall response rates: 31%, 31%, and 56%, respectively. Median overall survival durations were not reached in arm 1a and were 13 and 33 months for arms 1b and 2. Median progression-free survival: 8, 5, 10 months, respectively. Grades 3-4 treatment-related toxic effects for arms 1a, 1b, 2, respectively, were neutropenia 22%, 31%, 35%; thrombocytopenia 34%, 26%, 17%; and fatigue 2%, 14%, 13%. Conclusions: PLD plus carboplatin has moderate antitumor activity and excellent tolerability. Herceptin and PLD plus carboplatin in HER2-positive patients have antitumor activity without significant cardiac toxicity. Toxicity results suggest that PLD can be combined with Herceptin with minimal cardiac toxicity.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu